Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
AUTOR(ES)
Chilcott, Jim
FONTE
BMJ Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=150460Documentos Relacionados
- Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications
- The immunomodulator glatiramer acetate influences spinal motoneuron plasticity during the course of multiple sclerosis in an animal model
- Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis
- Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis